^
    1year
    NeoGenomics announces the commercial availability of two new tests, expanding its next-generation sequencing and lung cancer portfolios (NeoGenomics Press Release)
    "NeoGenomics, Inc...announced the commercial availability of two new tests, expanding its cancer portfolio of innovative products. These include Neo Comprehensive - Heme Cancers, a next-generation sequencing (NGS) panel with a comprehensive genomic profile of hematologic malignancies, and Early-stage Non-Small Cell Lung Cancer (NSCLC) Panel, a therapy selection panel designed specifically for early-stage NSCLC patients."
    Commercial
    |
    Early-stage NSCLC Panel • Neo Comprehensive™ - Heme Cancers